Masood Ahmed, MD
Interventional Cardiology · Newport News, VANPI 1093796310
Payments from drug & device makers
Across 144 payments — averaging $18.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$477
- Johnson & Johnson$347
- Amgen$320
- AstraZeneca$260
- Sanofi-aventis U.S. LLC$224
- Philips North America LLC$160
- plus $824 from 16 others
What the payments were for
- Food & beverage$2,55498%
- Education$582%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 35 | $477 |
| Johnson & Johnson | 21 | $347 |
| Amgen | 18 | $320 |
| AstraZeneca | 16 | $260 |
| Sanofi-aventis U.S. LLC | 11 | $224 |
| Philips North America LLC | 5 | $160 |
| Boehringer Ingelheim | 8 | $157 |
| Scpharmaceuticals Inc. | 3 | $95 |
| Astellas Pharma US Inc | 3 | $80 |
| Biotronik Inc. | 1 | $60 |
| Pfizer | 4 | $59 |
| Novartis | 3 | $57 |
| Braemar Manufacturing, LLC | 1 | $46 |
| Novo Nordisk | 2 | $40 |
| Medtronic(2 entities) | 3 | $39 |
| Medicomp Inc | 1 | $37 |
| Amarin Pharma, Inc. | 2 | $34 |
| Actelion Pharmaceuticals US, Inc. | 2 | $30 |
| Shockwave Medical, Inc | 1 | $26 |
| Bardy Diagnostics, Inc. | 2 | $25 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $20 |
| Preventice Services, LLC | 1 | $17 |
How this compares
$2,612 in reported general payments places this provider in the 30th percentile of 176 interventional cardiology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 311 | $304,190 |
| XareltoRivaroxaban | 118 | $127,862 |
| EntrestoSacubitril/Valsartan | 48 | $51,671 |
| MultaqDronedarone Hcl | 28 | $45,962 |
| BrilintaTicagrelor | 71 | $35,433 |
| FarxigaDapagliflozin Propanediol | 27 | $26,014 |
| Repatha SureclickEvolocumab | 25 | $18,725 |
| Praluent PenAlirocumab | 11 | $5,663 |
| Metoprolol Succinate | 482 | $4,529 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 122 | $2,815 |
| Amiodarone Hcl | 62 | $2,358 |
| Flecainide Acetate | 44 | $1,600 |
| Ranolazine ErRanolazine | 23 | $1,374 |
| Dilt-XrDiltiazem Hcl | 31 | $1,312 |
| Midodrine Hcl | 19 | $1,198 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $59 | $304,190311 claims |
| Johnson & JohnsonXarelto | $347 | $127,862118 claims |
| AstraZenecaBrilinta, Farxiga | $260 | $61,44898 claims |
| NovartisEntresto | $57 | $51,67148 claims |
| Sanofi-aventis U.S. LLCMultaq | $224 | $45,96228 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 176 interventional cardiology providers in Virginia.
Other interventional cardiology in Newport News
- Edward ChuNewport News$315K
- Deepak TalrejaVirginia Beach$2M
- Rajiv TayalFredericksburg$2M
- Michael RagostaCharlottesville$1M
- Jason FoerstRoanoke$956K
- Noah JonesFalls Church$907K
- John SaxonCharlottesville$900K
- Wayne BatchelorFalls Church$723K
- Matthew SummersNorfolk$614K
- Matthew SherwoodFalls Church$512K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.